Tafenoquine (cas 106635-80-7) for malaria prophylaxis in adults: An integrated safety analysis
-
Add time:07/31/2019 Source:sciencedirect.com
BackgroundTafenoquine (cas 106635-80-7) is a new prophylactic antimalarial drug. The current analysis presents an integrated safety assessment of the Tafenoquine Anticipated Clinical Regimen (Tafenoquine ACR) from 5 clinical trials, including 1 conducted in deployed military personnel and 4 in non-deployed residents, which also incorporated placebo and mefloquine comparator groups.
We also recommend Trading Suppliers and Manufacturers of Tafenoquine (cas 106635-80-7). Pls Click Website Link as below: cas 106635-80-7 suppliers
Prev:Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions
Next:Tafenoquine (cas 106635-80-7) is not neurotoxic following supertherapeutic dosing in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Artesunate-Tafenoquine (cas 106635-80-7) combination therapy promotes clearance and abrogates transmission of the avian malaria parasite Plasmodium gallinaceum08/03/2019
- Interactions between Tafenoquine (cas 106635-80-7) and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum08/02/2019
- Tafenoquine (cas 106635-80-7) is not neurotoxic following supertherapeutic dosing in rats08/01/2019